Search

Your search keyword '"Rodriguez-Aguayo, Cristian"' showing total 633 results
Start Over Author "Rodriguez-Aguayo, Cristian"
633 results on '"Rodriguez-Aguayo, Cristian"'

1. HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis

Author

Czopik, Agnieszka K., McNamee, Eóin N., Vaughn, Victoria, Huang, Xiangsheng, Bang, In Hyuk, Clark, Trent, Wang, Yanyu, Ruan, Wei, Nguyen, Tom, Masterson, Joanne C., Tak, Eunyoung, Frank, Sandra, Collins, Colm B., Li, Howard, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Gerich, Mark E., Furuta, Glenn T., Yuan, Xiaoyi, Sood, Anil K., de Zoeten, Edwin F., and Eltzschig, Holger K.

Published
2024
Full Text
View/download PDF

4. Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer

Author

Chakraborty, Debaditya, Ivan, Cristina, Amero, Paola, Khan, Maliha, Rodriguez-Aguayo, Cristian, Başağaoğlu, Hakan, and Lopez-Berestein, Gabriel

Subjects
Quantitative Biology - Genomics, Computer Science - Artificial Intelligence, Computer Science - Machine Learning
Abstract

We investigated the data-driven relationship between features in the tumor microenvironment (TME) and the overall and 5-year survival in triple-negative breast cancer (TNBC) and non-TNBC (NTNBC) patients by using Explainable Artificial Intelligence (XAI) models. We used clinical information from patients with invasive breast carcinoma from The Cancer Genome Atlas and from two studies from the cbioPortal, the PanCanAtlas project and the GDAC Firehose study. In this study, we used a normalized RNA sequencing data-driven cohort from 1,015 breast cancer patients, alive or deceased, from the UCSC Xena data set and performed integrated deconvolution with the EPIC method to estimate the percentage of seven different immune and stromal cells from RNA sequencing data. Novel insights derived from our XAI model showed that CD4+ T cells and B cells are more critical than other TME features for enhanced prognosis for both TNBC and NTNBC patients. Our XAI model revealed the critical inflection points (i.e., threshold fractions) of CD4+ T cells and B cells above or below which 5-year survival rates improve. Subsequently, we ascertained the conditional probabilities of $\geq$ 5-year survival in both TNBC and NTNBC patients under specific conditions inferred from the inflection points. In particular, the XAI models revealed that a B-cell fraction exceeding 0.018 in the TME could ensure 100% 5-year survival for NTNBC patients. The findings from this research could lead to more accurate clinical predictions and enhanced immunotherapies and to the design of innovative strategies to reprogram the TME of breast cancer patients., Comment: 14 pages, 5 figures, preprint

Published
2021

5. Enhancing oral delivery of plant-derived vesicles for colitis

Author

Liu, Yuan, Ahumada, Adrian Lankenau, Bayraktar, Emine, Schwartz, Paul, Chowdhury, Mamur, Shi, Sixiang, Sebastian, Manu M., Khant, Htet, de Val, Natalia, Bayram, Nazende Nur, Zhang, Guodong, Vu, Thanh Chung, Jie, Zuliang, Jennings, Nicholas B., Rodriguez-Aguayo, Cristian, Swain, Jody, Stur, Elaine, Mangala, Lingegowda S., Wu, Yutuan, Nagaraju, Supriya, Ermias, Brooke, Li, Chun, Lopez-Berestein, Gabriel, Braam, Janet, and Sood, Anil K.

Published
2023
Full Text
View/download PDF

7. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

Author

Zheng, Yiyan, Sethi, Ritika, Mangala, Lingegowda S., Taylor, Charlotte, Goldsmith, Juliet, Wang, Ming, Masuda, Kenta, Carrami, Eli M., Mannion, David, Miranda, Fabrizio, Herrero-Gonzalez, Sandra, Hellner, Karin, Chen, Fiona, Alsaadi, Abdulkhaliq, Albukhari, Ashwag, Fotso, Donatien Chedom, Yau, Christopher, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Knapp, Stefan, Gray, Nathanael S., Campo, Leticia, Myers, Kevin A., Dhar, Sunanda, Ferguson, David, Bast, Jr, Robert C., Sood, Anil K., von Delft, Frank, and Ahmed, Ahmed Ashour

Published
2022
Full Text
View/download PDF

8. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

Author

Lamhamedi-Cherradi, Salah-Eddine, Maitituoheti, Mayinuer, Menegaz, Brian A., Krishnan, Sandhya, Vetter, Amelia M., Camacho, Pamela, Wu, Chia-Chin, Beird, Hannah C., Porter, Robert W., Ingram, Davis R., Ramamoorthy, Vandhana, Mohiuddin, Sana, McCall, David, Truong, Danh D., Cuglievan, Branko, Futreal, P. Andrew, Velasco, Alejandra Ruiz, Anvar, Nazanin Esmaeili, Utama, Budi, Titus, Mark, Lazar, Alexander J., Wang, Wei-Lien, Rodriguez-Aguayo, Cristian, Ratan, Ravin, Livingston, J. Andrew, Rai, Kunal, MacLeod, A. Robert, Daw, Najat C., Hayes-Jordan, Andrea, and Ludwig, Joseph A.

Published
2022
Full Text
View/download PDF

9. HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis.

Author

Czopik, Agnieszka K., McNamee, Eóin N., Vaughn, Victoria, Huang, Xiangsheng, Bang, In Hyuk, Clark, Trent, Wang, Yanyu, Ruan, Wei, Nguyen, Tom, Masterson, Joanne C., Tak, Eunyoung, Frank, Sandra, Collins, Colm B., Li, Howard, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Gerich, Mark E., Furuta, Glenn T., Yuan, Xiaoyi, and Sood, Anil K.

Subjects
INFLAMMATORY bowel diseases, HYPOXIA-inducible factors, CELLULAR control mechanisms, CELL physiology, TRANSCRIPTION factors, T cells
Abstract

Metabolic imbalance leading to inflammatory hypoxia and stabilization of hypoxia-inducible transcription factors (HIFs) is a hallmark of inflammatory bowel diseases. We hypothesize that HIF could be stabilized in CD4+ T cells during intestinal inflammation and alter the functional responses of T cells via regulation of microRNAs. Our assays reveal markedly increased T cell-intrinsic hypoxia and stabilization of HIF protein during experimental colitis. microRNA screen in primary CD4+ T cells points us towards miR-29a and our subsequent studies identify a selective role for HIF-2α in CD4-cell-intrinsic induction of miR-29a during hypoxia. Mice with T cell-intrinsic HIF-2α deletion display elevated T-bet (target of miR-29a) levels and exacerbated intestinal inflammation. Mice with miR-29a deficiency in T cells show enhanced intestinal inflammation. T cell-intrinsic overexpression of HIF-2α or delivery of miR-29a mimetic dampen TH1-driven colitis. In this work, we show a previously unrecognized function for hypoxia-dependent induction of miR-29a in attenuating TH1-mediated inflammation. Inflammatory intestinal lesions are often hypoxic, which results in the stabilization and activation of hypoxia-inducible-factors (HIF). Here authors show that in a mouse model of colitis, HIF-2α is specifically stabilized in CD4+ type 1T helper (TH1) cells, leading to the upregulation of miR-29a expression and suppression of TH1 cell function, which pathway is potentially targetable for therapeutic purposes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside.

Author

Çakan, Elif, Lara, Olivia D., Szymanowska, Anna, Bayraktar, Emine, Chavez-Reyes, Arturo, Lopez-Berestein, Gabriel, Amero, Paola, and Rodriguez-Aguayo, Cristian

Subjects
CARRIER proteins, DRUG delivery systems, CELLULAR signal transduction, NUCLEOTIDES, MESSENGER RNA, MOLECULAR structure, TUMORS
Abstract

Simple Summary: Antisense oligonucleotide (ASO)-based drugs are a new class of compounds. In this review, we will discuss ASO technology, including improved delivery systems, enhanced stability, increased specificity, and challenges such as off-target effects and immune responses. ASO shows potential in cancer treatment by inhibiting the cell signaling pathways implicated in cancer progression. The inhibition of Grb2 is a potential target for ASO in leukemia treatment. This review may significantly impact the scientific community by providing a comprehensive overview of ASO-based therapies. Advancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics have emerged as a promising frontier in this realm, offering novel avenues for intervention such as RNA interference and the utilization of antisense oligonucleotides (ASOs). ASOs represent a versatile class of therapeutics capable of selectively targeting messenger RNAs (mRNAs) and silencing disease-associated proteins, thereby disrupting pathogenic processes at the molecular level. Recent advancements in chemical modification and carrier molecule design have significantly enhanced the stability, biodistribution, and intracellular uptake of ASOs, thereby bolstering their therapeutic potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, and parasitic diseases, our review manuscript focuses specifically on the application of ASOs in targeted cancer therapies. Through a comprehensive examination of the latest research findings and clinical developments, we delve into the intricacies of ASO-based approaches to cancer treatment, shedding light on their mechanisms of action, therapeutic efficacy, and prospects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site

Author

George, Jasmine, Li, Yongsheng, Kadamberi, Ishaque P., Parashar, Deepak, Tsaih, Shirng-Wern, Gupta, Prachi, Geethadevi, Anjali, Chen, Changliang, Ghosh, Chandrima, Sun, Yunguang, Mittal, Sonam, Ramchandran, Ramani, Rui, Hallgeir, Lopez-Berestein, Gabriel, Rodriguez-Aguayo, Cristian, Leone, Gustavo, Rader, Janet S., Sood, Anil K., Dey, Madhusudan, Pradeep, Sunila, and Chaluvally-Raghavan, Pradeep

Published
2021
Full Text
View/download PDF

13. RNA delivery for cancer gene therapy

Author

Oncul, Selin, primary, Amero, Paola, additional, Rodriguez-Aguayo, Cristian, additional, Sood, Anil K., additional, Calin, George A., additional, and Lopez-Berestein, Gabriel, additional

Published
2022
Full Text
View/download PDF

14. Contributors

Author

Alameh, Mohamad-Gabriel, primary, Alcantara, Marice, additional, Alluin, Jessica, additional, Amero, Paola, additional, Arechavala-Gomeza, Virginia, additional, Calin, George A., additional, Corey, David R., additional, Cramer, Hagen, additional, Dammes, Niels, additional, Drolet, Daniel W., additional, Frederiksen, James, additional, Gelinas, Amy D., additional, Habib, Nagy A., additional, Hazan-Halevy, Inbal, additional, Holm, Kevin, additional, Janjic, Nebojsa, additional, Johnson, Krystal C., additional, Johnson, Samantha T., additional, Kon, Edo, additional, Kortylewski, Marcin, additional, Landesman-Milo, Dalit, additional, Lemaitre, Marc M., additional, Lincoln, Christopher, additional, Lopez-Berestein, Gabriel, additional, Lynch, Sean A., additional, Oncul, Selin, additional, Ostroff, Rachel M., additional, Peer, Dan, additional, Rodriguez-Aguayo, Cristian, additional, Rohloff, John C., additional, Rossi, Daniel, additional, Rossi, John J., additional, Rupp, Thomas M., additional, Schneider, Daniel J., additional, Soblechero-Martín, Patricia, additional, Song, Min-Sun, additional, Sood, Anil K., additional, Su, Yu-Lin, additional, Sullenger, Bruce A., additional, Voutila, Jon, additional, Weissman, Drew, additional, Williams, Preston, additional, Yu, Chunsong, additional, Yu, Haixiang, additional, Zhang, Zhuoran, additional, and Zhou, Jiehua, additional

Published
2022
Full Text
View/download PDF

15. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Author

Haemmerle, Monika, Taylor, Morgan L, Gutschner, Tony, Pradeep, Sunila, Cho, Min Soon, Sheng, Jianting, Lyons, Yasmin M, Nagaraja, Archana S, Dood, Robert L, Wen, Yunfei, Mangala, Lingegowda S, Hansen, Jean M, Rupaimoole, Rajesha, Gharpure, Kshipra M, Rodriguez-Aguayo, Cristian, Yim, Sun Young, Lee, Ju-Seog, Ivan, Cristina, Hu, Wei, Lopez-Berestein, Gabriel, Wong, Stephen T, Karlan, Beth Y, Levine, Douglas A, Liu, Jinsong, Afshar-Kharghan, Vahid, and Sood, Anil K

Subjects
Blood Platelets, Cell Line, Tumor, Animals, Mice, Inbred C57BL, Humans, Mice, Nude, Ovarian Neoplasms, Neoplasm Metastasis, Adaptor Proteins, Signal Transducing, Phosphoproteins, Transplantation, Heterologous, Coculture Techniques, Gene Expression Profiling, Signal Transduction, Anoikis, RNA Interference, Female, Transcription Factors, Rare Diseases, Cancer, 2.1 Biological and endogenous factors, Cell Line, Tumor, Mice, Inbred C57BL, Nude, Adaptor Proteins, Signal Transducing, Transplantation, Heterologous
Abstract

Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates with worsened patient survival. Tumor cell interaction with various cellular components of the tumor microenvironment including platelets is crucial for tumor growth and metastasis. Although it is known that platelets can infiltrate into tumor tissue, secrete pro-angiogenic and pro-tumorigenic factors and thereby increase tumor growth, the precise molecular interactions between platelets and metastatic cancer cells are not well understood. Here we demonstrate that platelets induce resistance to anoikis in vitro and are critical for metastasis in vivo. We further show that platelets activate RhoA-MYPT1-PP1-mediated YAP1 dephosphorylation and promote its nuclear translocation which induces a pro-survival gene expression signature and inhibits apoptosis. Reduction of YAP1 in cancer cells in vivo protects against thrombocytosis-induced increase in metastasis. Collectively, our results indicate that cancer cells depend on platelets to avoid anoikis and succeed in the metastatic process.Platelets have been associated with increased tumor growth and metastasis but the mechanistic details of this interaction are still unclear. Here the authors show that platelets improve anoikis resistance of cancer cells and increase metastasis by activating Yap through a RhoA/MYPT-PP1 pathway.

Published
2017

16. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

Author

Joseph, Robiya, primary, Dasari, Santosh K., additional, Umamaheswaran, Sujanitha, additional, Mangala, Lingegowda S., additional, Bayraktar, Emine, additional, Rodriguez-Aguayo, Cristian, additional, Wu, Yutuan, additional, Nguyen, Nghi, additional, Powell, Reid T., additional, Sobieski, Mary, additional, Liu, Yuan, additional, Kim, Mark Seungwook, additional, Corvigno, Sara, additional, Foster, Katherine, additional, Hanjra, Pahul, additional, Vu, Thanh Chung, additional, Chowdhury, Mamur A., additional, Amero, Paola, additional, Stephan, Clifford, additional, Lopez-Berestein, Gabriel, additional, Westin, Shannon N., additional, and Sood, Anil K., additional

Published
2024
Full Text
View/download PDF

19. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis

Author

Xu, Xiaoyan, Wang, Yumeng, Mojumdar, Kamalika, Zhou, Zhicheng, Jeong, Kang Jin, Mangala, Lingegowda S., Yu, Shuangxing, Tsang, Yiu Huen, Rodriguez-Aguayo, Cristian, Lu, Yiling, Lopez-Berestein, Gabriel, Sood, Anil K., Mills, Gordon B., and Liang, Han

Subjects
Thermo Fisher Scientific Inc., Apoptosis, MicroRNA, Cancer -- Development and progression, Cancer research, Scientific equipment industry, Therapeutics, RNA, Tumors, Health care industry, University of Texas. M.D. Anderson Cancer Center
Abstract

Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics., Introduction Adenosine-to-inosine (A-to-I) RNA editing is a widespread posttranscriptional mechanism in humans that is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes and introduces specific nucleotide changes at the [...]

Published
2019
Full Text
View/download PDF

23. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma

Author

Shahzad, Mian MK, Shin, Yong-Hyun, Matsuo, Koji, Lu, Chunhua, Nishimura, Masato, Shen, De-Yo, Kang, Yu, Hu, Wei, Mora, Edna M, Rodriguez-Aguayo, Cristian, Kapur, Arvinder, Bottsford-Miller, Justin, Lopez-Berestein, Gabriel, Rajkovic, Aleksandar, and Sood, Anil K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Ovarian Cancer, Cancer, Biotechnology, Genetics, Orphan Drug, 2.1 Biological and endogenous factors, Aetiology, Animals, Carcinoma, Ovarian Epithelial, Cell Cycle Proteins, Cell Line, Tumor, Female, Humans, Mice, Neoplasm Invasiveness, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, RNA, Messenger, RNA, Small Interfering, Tumor Microenvironment, Vascular Endothelial Growth Factor A, HORMAD1, Ovarian cancer, Angiogenesis, VEGF, Xenograft, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.

Published
2013

25. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression

Author

Rupaimoole, Rajesha, Wu, Sherry Y., Pradeep, Sunila, Ivan, Cristina, Pecot, Chad V., Gharpure, Kshipra M., Nagaraja, Archana S., Armaiz-Pena, Guillermo N., McGuire, Michael, Zand, Behrouz, Dalton, Heather J., Filant, Justyna, Miller, Justin Bottsford, Lu, Chunhua, Sadaoui, Nouara C., Mangala, Lingegowda S., Taylor, Morgan, van den Beucken, Twan, Koch, Elizabeth, Rodriguez-Aguayo, Cristian, Huang, Li, Bar-Eli, Menashe, Wouters, Bradly G., Radovich, Milan, Ivan, Mircea, Calin, George A., Zhang, Wei, Lopez-Berestein, Gabriel, and Sood, Anil K.

Published
2020
Full Text
View/download PDF

26. Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

Author

Dragomir, Mihnea P., primary, Fuentes-Mattei, Enrique, additional, Winkle, Melanie, additional, Okubo, Keishi, additional, Bayraktar, Recep, additional, Knutsen, Erik, additional, Qdaisat, Aiham, additional, Chen, Meng, additional, Li, Yongfeng, additional, Shimizu, Masayoshi, additional, Pang, Lan, additional, Liu, Kevin, additional, Liu, Xiuping, additional, Anfossi, Simone, additional, Zhang, Huanyu, additional, Koch, Ines, additional, Tran, Anh M., additional, Mohapatra, Swati, additional, Ton, Anh, additional, Kaplan, Mecit, additional, Anderson, Matthew W., additional, Rothfuss, Spencer J., additional, Silasi, Robert, additional, Keshari, Ravi S., additional, Ferracin, Manuela, additional, Ivan, Cristina, additional, Rodriguez-Aguayo, Cristian, additional, Lopez-Berestein, Gabriel, additional, Georgescu, Constantin, additional, Banerjee, Pinaki P., additional, Basar, Rafet, additional, Li, Ziyi, additional, Horst, David, additional, Vasilescu, Catalin, additional, Bertilaccio, Maria Teresa S., additional, Rezvani, Katayoun, additional, Lupu, Florea, additional, Yeung, Sai-Ching, additional, and Calin, George A., additional

Published
2023
Full Text
View/download PDF

32. Abstract 1463: Fxr1 is an oncogenic driver in ovarian cancer

Author

George, Jasmine, primary, Kadamberi, Ishaque P., additional, Geethadevi, Anjali, additional, Kumar, Sudhir, additional, Mittal, Sonam, additional, Rodriguez-Aguayo, Cristian, additional, Mangala, Lingegowda S., additional, Sood, Anil K., additional, Pradeep, Sunila, additional, and Chaluvally-Raghavan, Pradeep, additional

Published
2023
Full Text
View/download PDF

33. Abstract 2720: Enhancing oral delivery of plant-derived vesicles

Author

Liu, Yuan, primary, Lankenau-Ahumada, Adrian, additional, Bayraktar, Emine, additional, Schwartz, Paul, additional, Chowdhury, Mamur, additional, Shi, Sixiang, additional, Sebastian, Manu M., additional, Khant, Htet, additional, De Val, Natalia, additional, Jie, Zuliang, additional, Jennings, Nicholas B., additional, Rodriguez-Aguayo, Cristian, additional, Swain, Jody, additional, Stur, Elaine, additional, Mangala, Lingegowda S., additional, Wu, Yutuan, additional, Nagaraju, Supriya, additional, Erimas, Brooke, additional, Li, Chun, additional, Lopez-Berestein, Gabriel, additional, Braam, Janet, additional, and Sood, Anil K., additional

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

Author

Handley, Katelyn F., primary, Rodriguez-Aguayo, Cristian, primary, Ma, Shaolin, primary, Stur, Elaine, primary, Joseph, Robiya, primary, Bayraktar, Emine, primary, Dasari, Santosh K., primary, Nguyen, Nghi, primary, Powell, Reid T., primary, Sobieski, Mary, primary, Ivan, Cristina, primary, Kim, Mark, primary, Umamaheswaran, Sujanitha, primary, Glassman, Deanna, primary, Wen, Yunfei, primary, Amero, Paola, primary, Stephan, Clifford, primary, Coleman, Robert L., primary, Landesman, Yosef, primary, Westin, Shannon N., primary, Ram, Prahlad T., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

37. Data from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Author

Ma, Shaolin, primary, Pradeep, Sunila, primary, Villar-Prados, Alejandro, primary, Wen, Yunfei, primary, Bayraktar, Emine, primary, Mangala, Lingegowda S., primary, Kim, Mark Seungwook, primary, Wu, Sherry Y., primary, Hu, Wei, primary, Rodriguez-Aguayo, Cristian, primary, Leuschner, Carola, primary, Liang, Xiaoyan, primary, Ram, Prahlad T., primary, Schlacher, Katharina, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Author

Ma, Shaolin, primary, Pradeep, Sunila, primary, Villar-Prados, Alejandro, primary, Wen, Yunfei, primary, Bayraktar, Emine, primary, Mangala, Lingegowda S., primary, Kim, Mark Seungwook, primary, Wu, Sherry Y., primary, Hu, Wei, primary, Rodriguez-Aguayo, Cristian, primary, Leuschner, Carola, primary, Liang, Xiaoyan, primary, Ram, Prahlad T., primary, Schlacher, Katharina, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

39. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

40. Data from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

Author

Nishimura, Masato, primary, Jung, Eun-Jung, primary, Shah, Maitri Y., primary, Lu, Chunhua, primary, Spizzo, Riccardo, primary, Shimizu, Masayoshi, primary, Han, Hee Dong, primary, Ivan, Cristina, primary, Rossi, Simona, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Wu, Sherry Y., primary, Almeida, Maria Ines, primary, Bottsford-Miller, Justin, primary, Pecot, Chad V., primary, Zand, Behrouz, primary, Matsuo, Koji, primary, Shahzad, Mian M., primary, Jennings, Nicholas B., primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

44. Data from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure Legends, Materials and Methods, and Table 1 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

47. Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figures 1 - 2 from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

Author

Pecot, Chad V., primary, Wu, Sherry Y., primary, Bellister, Seth, primary, Filant, Justyna, primary, Rupaimoole, Rajesha, primary, Hisamatsu, Takeshi, primary, Bhattacharya, Rajat, primary, Maharaj, Anshumaan, primary, Azam, Salma, primary, Rodriguez-Aguayo, Cristian, primary, Nagaraja, Archana S., primary, Morelli, Maria Pia, primary, Gharpure, Kshipra M., primary, Waugh, Trent A., primary, Gonzalez-Villasana, Vianey, primary, Zand, Behrouz, primary, Dalton, Heather J., primary, Kopetz, Scott, primary, Lopez-Berestein, Gabriel, primary, Ellis, Lee M., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figures 1-7 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results